Global Acute Heart Failure (AHF) Therapeutics Industry

Global Acute Heart Failure (AHF) Therapeutics Industry

  • April 2021 •
  • 267 pages •
  • Report ID: 6051401 •
  • Format: PDF
Abstract:
- Global Acute Heart Failure (AHF) Therapeutics Market to Reach $1.5 Billion by 2027
- Amid the COVID-19 crisis, the global market for Acute Heart Failure (AHF) Therapeutics estimated at US$372.9 Million in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 22.2% over the analysis period 2020-2027. Cardiac Glycosides, one of the segments analyzed in the report, is projected to record a 22.3% CAGR and reach US$391 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the B-Blockers segment is readjusted to a revised 25.6% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $100.4 Million, While China is Forecast to Grow at 27.6% CAGR
- The Acute Heart Failure (AHF) Therapeutics market in the U.S. is estimated at US$100.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$363.8 Million by the year 2027 trailing a CAGR of 27.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.5% and 20.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 19% CAGR.
- Calcium Channel Blockers Segment to Record 24.2% CAGR
- In the global Calcium Channel Blockers segment, USA, Canada, Japan, China and Europe will drive the 23.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$42.6 Million in the year 2020 will reach a projected size of US$184.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$226.8 Million by the year 2027, while Latin America will expand at a 25.5% CAGR through the analysis period.

- Select Competitors (Total 93 Featured) -
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cardiorentis AG
  • CVie Therapeutics Limited
  • Cytokinetics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • PhaseBio Pharmaceuticals, Inc.